HR 2212 · 115th Congress 2017–2019, ended

CREATES Act of 2017

Latest action · Apr 28, 2017 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedApr 27, 2017
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017

This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.

Cosponsors 25

Members who signed on, in the order they did. Signatures ran from Apr 27, 2017 to Sep 28, 2018; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-RIDavid N. CicillineOriginalApr 27, 2017
R-NCMark MeadowsFeb 6, 2018
D-VTPeter WelchFeb 6, 2018
D-TNSteve CohenFeb 8, 2018
R-INTodd RokitaFeb 8, 2018
R-FLFrancis RooneyFeb 20, 2018
D-OHMarcy KapturFeb 20, 2018
D-NHCarol Shea-PorterFeb 23, 2018
R-WIMike GallagherFeb 23, 2018
D-DCEleanor Holmes NortonMar 8, 2018
R-TNJohn J. Duncan, Jr.Mar 8, 2018
R-TXJohn Abney CulbersonMar 13, 2018
D-TXLloyd DoggettMar 13, 2018
D-MSBennie G. ThompsonMar 15, 2018
R-VADave BratMar 15, 2018
R-OHBob GibbsApr 17, 2018
D-ILJanice D. SchakowskyApr 17, 2018
R-KYAndy BarrMay 3, 2018
D-ORPeter A. DeFazioMay 3, 2018
D-TXBeto O'RourkeJun 6, 2018
R-OHJames B. RenacciJun 6, 2018
D-MDJamie RaskinAug 10, 2018
R-NYPeter T. KingAug 10, 2018
D-ILDaniel LipinskiSep 28, 2018
R-WIGlenn GrothmanSep 28, 2018

Committees 2

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Apr 27, 2017
Health Subcommittee
Referred Apr 28, 2017
HouseJudiciary Committee
Referred Apr 27, 2017

Actions 3

Everything that happened, newest first.

  1. Apr 28, 2017Referred to the Subcommittee on Health.
  2. Apr 27, 2017Introduced in House
  3. Apr 27, 2017Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article I, Section I, Clause 1 of the U.S. Constitution, in that the legilation concems the exercise of legislative powers generally granted to Congress, including the exercise of those powers when delegated by Congress to the Executive. Article I, Section 8, Clause 3 of the U.S. Constitution in that the legislation exercises legislative powers granted to Congress by that clause ``to regulate Commerce with foreign Nations, and among the several States, and with the Indian Tribes.'' and Article I, Section 8, Clause 18 of the U.S. Constitution in that the legislation exercises legislative powers granted to Congress by that clause ``to make all Laws which shall be necessary and proper for carrying into Execution the foregoing Powers, and all other Powers vested by this Constitution in the Government of the United States, or in any Department or Office thereof.''

The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 72, April 27, 2017, page H2942.

Printed hearings 2

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
Serial No. 115-28THE PHARMACEUTICAL SUPPLY CHAIN: THE PROPOSED MERGER OF CVS HEALTH AND AETNA43 pagesJudiciary CommitteeFeb 27, 2018
S. Hrg. 115-869THE COST OF PRESCRIPTION DRUGS: AN EXAMINATION OF THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE REPORT "MAKING MEDICINES AFFORDABLE: A NATIONAL IMPERATIVE"60 pagesHealth, Education, Labor, and Pensions CommitteeDec 12, 2017

CRS reports 2

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 2

Products on other subjects that cite it, usually among other measures.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 974CREATES Act of 2018Identical billJun 21, 2018

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Short Titles as Introduced
CREATES Act of 2017
Creating and Restoring Equal Access To Equivalent Samples Act of 2017

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Apr 27, 2017Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.